Why was the cohort set up?
==========================

Influenza is a common, highly contagious respiratory virus which infects all age groups, causing a range of outcomes from asymptomatic infection and mild respiratory disease to severe respiratory disease and death.[@dyv370-B1] If infected, the adaptive immune system produces a humoral (antibody) and cell-mediated (T cell) immune response to fight the infection.[@dyv370-B2] Influenza viruses continually evolve through antigenic drift, resulting in slightly different 'seasonal' influenza strains circulating each year. Population-level antibody immunity to these seasonal viruses builds up over time, so in any given season only a proportion of the population is susceptible to the circulating strains. Occasionally, influenza A viruses evolve rapidly through antigenic shift by swapping genes with influenza viruses usually circulating in animals. This process creates an immunologically distinct virus to which the population may have little to no antibody immunity. The virus can result in a pandemic if a large portion of the population is susceptible and the virus is easily spread.[@dyv370-B1]

International influenza surveillance is typically based upon cases seeking medical care.[@dyv370-B3] However, this focus greatly underestimates the true community burden of seasonal influenza: the majority of cases are mild and self-limiting, with asymptomatic infections accounting for 25% to 75% of all infections.[@dyv370-B6]^,^[@dyv370-B7] Effective influenza control requires knowledge of disease burden and factors affecting influenza transmission. Existing parameters for mathematical models of influenza interventions are largely derived from household cohort studies conducted in the USA between 1948 and 1981.[@dyv370-B8] Since then there have been profound social changes affecting population contact and mixing patterns that are likely to impact on influenza transmission. These changes include more women working, more children attending day care, more commuting and international travel and increased vaccine coverage. Evolutionary changes to circulating viruses may affect transmission dynamics, patterns of clinical illness and the adaptive immune responses elicited.[@dyv370-B1]^,^[@dyv370-B11] Rapid advances in laboratory methods have also occurred, providing unique opportunities to investigate immune correlates, both humoral and T cell based, with influenza infection rates and disease severity.[@dyv370-B11]^,^[@dyv370-B12]

The initial Flu Watch cohort, funded by the UK Medical Research Council (MRC), began in 2006 as a collaboration between epidemiologists at the Centre for Infectious Disease Epidemiology at University College London (UCL), virologists and mathematical modellers from the Health Protection Agency (HPA, now Public Health England), immunologists at the MRC Human Immunology Unit at Oxford University and the MRC General Practice Research Framework (GPRF). It aimed to estimate community burden of influenza and influenza-like illness, generate up-to-date knowledge of demographic, social and behavioural factors affecting influenza transmission, measure antibody and T cell immune responses to influenza and to use knowledge generated to inform modelling parameters. In addition, a pandemic preparedness cohort was envisioned, in which participants already familiar with the study consented to be re-contacted in the event of a pandemic, to allow rapid redeployment of the study.

When the 2009 influenza AH1N1 pandemic arose, further funding was secured jointly from the MRC and Wellcome Trust, allowing continued follow-up and an expansion in cohort size. New collaborators for this phase included the MRC Centre for Outbreak Analysis and Modelling, the Wellcome Sanger Institute, the Primary Care Research Network and additional epidemiology and public health experts from the HPA. Additional study aims were to inform the national and international response to the current and future pandemics. Specific objectives were to examine clinical profiles of illness, estimate population infection denominators and case fatality risk, describe epidemiological characteristics of the infection in real-time, monitor changes in population behaviour, and investigate access to services, attitudes to and uptake of antivirals and vaccine, and immunity to infection in order to inform vaccination policy and development. During the pandemic, Flu Watch also provided control data and samples for studies of severe influenza (MOSAIC) and studies of influenza infection risk in people working with pigs (COSI).[@dyv370-B13]^,^[@dyv370-B14]

Who is in the cohort?
=====================

Households were recruited from registers of 146 volunteer general practices (GP) across England, who formed part of the MRC GPRF or (from the 2009 pandemic onwards) the Primary Care Research Network. Participants were selected from GP lists by computer-based random number generation. GPs sent invitation letters inviting the randomly selected person and their household to participate. Although it was recognized that this would bias invitations towards larger households, such as those with children, this was accepted as the role of children in influenza transmission was an important research question. Weighting by the inverse of household size in analyses was planned to account for this sampling design.

To be eligible to participate, the whole household had to agree to take part in follow-up over the coming winter, with adults aged ≥ 16 years agreeing to have blood samples taken. Exclusion criteria included household size \> 6 people, individuals with terminal illness, severe mental illness or incapacity and heavy involvement in other ongoing research. GPs reviewed invitation lists and removed anyone meeting these criteria, before sending letters. Cohorts were recruited to allow follow-up of participants over six influenza seasons---the 2006/07, 2007/08 and 2008/09 periods of seasonal influenza circulation, the summer and winter waves of the 2009 pandemic and the first post-pandemic season 2010/11. From season 3 (2008/09) onwards, previous participants were invited to take part again.

In season 1, invitation letters were sent to 2300 households from 42 practices, and 602 individuals from 243 households agreed to participate. In subsequent seasons the response rate was not monitored as practices (rather than the university study team) sent the invitation letters and not all returned data on numbers sent. Compared with the English population, young adults, non-White ethnic groups, people living in socially deprived areas and those living in the North of England, West Midlands and London were under-represented in the Flu Watch cohort ([Table 1](#dyv370-T1){ref-type="table"}). Table 1.Baseline characteristics of responders by season compared with national averagesNationalNov 2006 to Mar 2007 Season 1Nov 2007 to Mar 2008 Season 2Nov 2008 to Mar 2009 Season 3May 2009 to Sep 2009 Season 4Oct 2009 to Feb 2010 Season 5Nov 2010 to Mar 2011 Season 6**GP practices/ households/ persons (*n*)**42/243/60243/310/77937/309/72941/332/797127/1460/355251/361/901**Age group** 0 to 4 years6%38 (6.31%)42 (5.39%)37 (5.08%)36 (4.52%)179 (5.04%)45 (4.99%) 5 to 1511%87 (14.45%)110 (14.12%)99 (13.58%)109 (13.68%)501 (14.10%)131 (14.54%) 16 to 4442%151 (25.08%)258 (33.12%)172 (23.59%)192 (24.09%)848 (23.87%)206 (22.86%) 45 to 6425%203 (33.72%)272 (34.92%)267 (36.63%)293 (36.76%)1225 (34.49%)344 (38.18%) 65+16%123 (20.43%)97 (12.45%)154 (21.12%)167 (20.95%)799 (22.49%)175 (19.42%)**Gender** Male49%281 (46.68%)366 (46.98%)340 (46.64%)377 (47.30%)1740 (48.99%)455 (50.50%) Female51%321 (53.32%)413 (53.02%)389 (53.36%)420 (52.70%)1812 (51.01%)446 (49.50%)**Region** North28%99 (16.45%)89 (11.42%)100 (13.72%)106 (13.30%)320 (9.01%)115 (12.76%) West Midlands11%42 (6.98%)96 (12.32%)46 (6.31%)53 (6.65%)179 (5.04%)53 (5.88%) East & East Midlands20%122 (20.27%)120 (15.40%)124 (17.01%)118 (14.81%)1456 (40.99%)321 (35.63%) London15%28 (4.65%)77 (9.88%)26 (3.57%)28 (3.51%)270 (7.60%)65 (7.21%) South East16%100 (16.61%)117 (15.02%)107 (14.68%)155 (19.45%)319 (8.98%)110 (12.21%) South West10%211 (35.05%)280 (35.94%)326 (44.72%)337 (42.28%)1008 (28.38%)237 (26.30%)**Vaccine** Vaccinated^a^115 (19.10%)130 (16.69%)169 (23.18%)0 (0%)157 (4.42%)186 (20.64%) Unvaccinated462 (76.74%)632 (81.13%)527 (72.29%)797 (100%)3159 (88.94%)715 (79.36%) Unknown25 (4.15%)17 (2.18%)33 (4.53%)0 (0%)236 (6.64%)0 (0%)**Index of Multiple Deprivation quintile** 1 (most deprived)20%37 (6.15%)39 (5.01%)28 (3.84%)18 (2.26%)98 (2.76%)29 (3.22%) 220%88 (14.62%)126 (16.17%)91 (12.48%)62 (7.78%)310 (8.73%)82 (9.10%) 320%164 (27.24%)235 (30.17%)238 (32.65%)146 (18.32%)915 (25.76%)221 (24.53%) 420%162 (26.91%)250 (32.09%)187 (25.65%)146 (18.32%)938 (26.41%)280 (31.08%) 5 (least deprived)20%151 (25.08%)129 (16.56%)185 (25.38%)425 (53.32%)1291 (56.35%)289 (32.08%)**Ethnicity**  White75%557 (97.89%)733 (95.44%)666 (99.11%)730 (99.05%)3306 (97.70%)846 (97.80%) Non-White25%5 (2.11%)3 (4.56%)6 (0.89%)7 (0.95%)78 (2.30%)19 (2.20%)[^1]

How often have they been followed up?
=====================================

The basic cohort design
-----------------------

### Baseline/pre-season phase

A baseline visit was made to the household at enrolment, during which a research nurse collected blood samples for serological and T cell analysis from all adults aged 16 years or older. Blood sampling was optional for those aged 5--15 years and not done in those under 5 years of age. Visits occurred in the evenings, as bloods had to be couriered overnight to Oxford for early morning analysis of T cells. The serum samples collected we recentrifuged, frozen and later batch-tested for influenza antibodies by the HPA. Nurses assisted families with a series of laptop-based surveys collecting information on basic demographics, health and chronic illness, respiratory hygiene, household structure and relationships, accommodation, contacts and activities. Households received participant packs containing paper illness diaries, thermometers and nasal swab kits including instructions on their use and the viral transport medium to be stored in the refrigerator.

### Active follow-up during influenza season

In order to obtain reliable measures of the number of illnesses, we actively contacted participants every week with automated telephone calls to assess the presence or absence of respiratory illness in each household member. For each respiratory illness, participants were reminded to fill in a prospective paper illness diary. These collected information on illness onset date, temperature and presence and severity of symptoms such as feeling feverish, headache, muscle aches, cough and sore throat. Diaries also collected data on contact patterns and activities before and during illness. Participants took a nasal swab on day 2 of any respiratory illness for polymerase chain reaction (PCR) analysis of influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinovirus, coronavirus, adenovirus and parainfluenzavirus. During the first season, swabbing was limited to periods of influenza circulation. The Sanger Institute genetically sequenced some of the viral isolates from the summer and winter waves of the pandemic (seasons 4--5).

In addition, all participants completed one-off activity and contact paper diaries on at least 1 pre-determined weekday and 1 weekend day during the active follow-up period. These diaries collected information on where participants were (i.e. at home, at work etc.), whether they had contact with crowds and the number, duration and age groups of personal contacts throughout the day.

### Post-season phase

At the end of follow-up, nurses made a final household visit to take a follow-up blood sample (for paired serology) and assist participants with an exit survey. Nurses also checked participants' medical records for information on chronic illnesses, influenza and pneumococcal vaccinations, prescriptions, GP consultations, hospitalizations and deaths.

Evolution of data collection
----------------------------

The cohort evolved over time to maximize system reliability, minimize the number of data sources and allow increased recruitment during the pandemic. In season 3 we offered participants the option of moving from paper illness diaries with weekly automated phone calls to weekly emailed surveys with or without optional SMS reminders. For the pandemic and post-pandemic cohort, most surveys moved to a custom-built website for self-completion. In order to achieve real-time monitoring of illnesses during the pandemic, participants were emailed a link to a retrospective online weekly survey and provided with laminated wipe-clean charts at home to record daily symptoms as a memory aid.

In season 3 there were additional one-off surveys collecting data on indoor and outdoor temperature and humidity, travel patterns and non-response to weekly surveys. During seasons 5 and 6 we added questions to existing surveys on attitudes towards influenza vaccination and antivirals. In season 6 we included quality of life questions.[@dyv370-B15]

Evolution of cohort design
--------------------------

The cohort design evolved with the emergence of the novel H1N1 pandemic strain during season 3.We continued active follow-up through the UK summer wave of the pandemic (season 4). For the UK winter wave of the pandemic (season 5), the study split into three separate cohorts: T cell (comprising both previous and newly recruited participants), Serology and Virology (both comprising new participants). For the T cell cohort, continuing participants used the spring blood sample from season 3 as a baseline sample. They also gave a pre-vaccination blood sample to allow distinction of antibody rises caused by infection rather than vaccination. This was particularly important for the winter wave of the pandemic, as we anticipated widespread vaccination. The Serology cohort was identical but lacked T cell samples. For the Virology cohort, no blood samples were taken. This allowed for rapid recruitment of a large number of participants (*n* = 1778) to increase the accuracy of weekly estimates of illness rates during the pandemic, with minimal nurse time required. All nasal swabs were tested for influenza A and B, RSV and hMPV but, due to the large number of samples generated during the pandemic, only a selection in seasons 5 and 6 were tested for other viruses.

Loss to follow-up and missing data
----------------------------------

Retention of enrolled participants throughout the cohorts was good. [Figure 1](#dyv370-F1){ref-type="fig"} displays the number of enrolled participants each week, with arrows pointing out the staggered starts and exits of the cohorts along with other important dates. Loss to follow-up came in two main varieties: non-response to weekly contact and loss to follow-up for paired blood samples.

![Number of enrolled participants, baseline/pre-season bleed periods and different cohorts and data collection methods over time. 'Survey Methods' boxes used to indicate which methods were used to follow up participants in each season \*T cell cohorts included T cell, serological and virological (PCR) measurements. \*\* Serology cohorts included serological and virological (PCR) measurements. \*\*\* Virology cohort only included virological (PCR) measurements.](dyv370f1){#dyv370-F1}

We obtained weekly responses from 87.3% of follow-up weeks overall, which increased to 88.4% if we exclude periods when there were technical difficulties with our automated phone calls (1 week in season 1 and 4 weeks in season 2). Response completeness generally increased after the introduction of email and online surveys in season 3 ([Table 2](#dyv370-T2){ref-type="table"}). Only 12.4% of households were classified as poor responders (responding to \< 70% of follow-up weeks). Poor response appeared to be more common as deprivation increased. Table 2.Characteristics of non-responding households (i.e. households with ≥ 30% missing weeks)Household characteristicsGood respondersPoor respondersTotal(\< 30% missing weeks)(≥ 30% missing weeks)*N*%*N*%*N***Overall**264087.637212.43012**Season** Nov 2006 to Mar 2007 (1)19981.94418.1243 Nov 2007 to Mar 2008 (2)20265.810534.2307 Nov 2008 to Mar 2009 (3)28792.9227.1309 May 2009 to Sep 2010 (4)24674.18625.9\*332 Oct 2009 to Feb 2010 (5)137093.8906.21460 Nov 2010 to Mar 2011 (6)33693.1256.9361**Social class** Managerial and professional71287.610112.4813 Intermediate occupations36287.95012.1412 Small employers and own-account workers20985.33614.7245 Lower supervisory and technical occupations11184.12115.9132 Semi-routine and routine occupations44186.56913.5510 Retired49794326529 Student10984.52015.5129 missing19982.24317.8242**Index of Multiple Deprivation quintile** 1 (most deprived)85812019105 225584.74615.3301 370486.910613.1810 473289.68510.4817 5 (least deprived)86488.311511.7979**Rural/urban** Urban \> 10k150586.723013.31735 Town and fringe37390.3409.7413 Village, hamlet and isolated dwellings64389.97210.1715 Missing11979.93020.1149**Household size** 135484.56515.5419 2140589.716210.31567 334485.16014.9404 440787.35912.7466 510984.52015.5129 62177.8622.227**Number of children in the household** 0193289.123610.92168 124781.85518.2302 236085.16314.9423 38386.51313.596 41878.3521.723**Region** North30587.94212.1347 West Midlands16484.13115.9195 East and East Midlands82890.5879.5915 London16484.53015.5194 South East31483.56216.5376 South West86587.812012.2985[^2]

We obtained paired blood samples from 80% of participants required to provide them and from 27% of participants aged 15 and under, for whom blood samples were optional ([Table 3](#dyv370-T3){ref-type="table"}). Table 3.Characteristics of Participants with and without missing blood samples by whether or not those blood samples were required or optionalIndividual characteristicsParticipants with Mandatory BloodsParticipants with Optional BloodsPaired BloodsMissing BloodTotalPaired BloodsMissing BloodTotal*N*%*N*%*NN*%*N*%*N***Overall**311480.575419.5386818127.048973.0670**Season** Nov 2006 to Mar 2007 (1)42288.55511.54773135.65664.487 Nov 2007 to Mar 2008 (2)50380.212419.86272724.58375.5110 Nov 2008 to Mar 2009 (3)48982.510417.55932323.27676.899 Oct 2009 to Feb 2010 (5)112077.532622.514467028.817371.2243 Nov 2010 to Mar 2011 (6)58080.014520.07253022.910177.1131**Gender** Male144179.836320.118049527.724872.3343 Female167381.039118.920648626.324173.7327**Age group** Age 5 to 15 yearsn/an/a18127.048973.0670 Age 16 to 44 years87474.030726.01181n/an/a Age 45 to 64 years144682.430917.61755n/an/a Age 65 and over79485.213814.8932n/an/a**Region** North36573.912926.14942528.16471.989 West Midlands23184.34315.72741023.83276.242 East & East Midlands81779.720820.310254323.014477.0187 London15884.52915.51871330.23069.843 South East44479.711320.35572533.35066.775 South West109982.623217.413316527.816972.2234**Vaccine** Vaccinated^a^95384.018116.011341429.83370.247 Unvaccinated207281.148418.9255416527.942772.1592 Unknown8949.49150.618026.52993.531**Index of Multiple Deprivation (National quintile)** 1 (most deprived)11086.61713.4127620.72379.329 236384.66615.44292128.45371.674 389381.819918.210925930.113769.9196 492283.318516.711075027.513272.5182 5 (least deprived)82674.228725.811134523.814476.2189**Ethnicity** White265482.855117.2320516129.139270.9553 Non-White4970.02130.07019.11090.911 Missing41169.318230.75931917.98782.1106**Rural/Urban** Urban189582.540317.5229811626.332573.7441 Town and Fringe42682.49117.65172333.34666.769 Village, hamlet and isolated Dwellings79382.117317.99664230.99469.1136 Missing00.087100.08700.024100.024[^3]

What has been measured?
=======================

The three main clinical outcomes were: (i) influenza-like-illness (ILI), defined as a respiratory illness with cough and/or sore throat and fever \> 37.8°C;(ii) PCR-confirmed influenza illness; and (iii) influenza seroconversion, defined as a 4-fold titre rise in strain-specific antibody titres in unvaccinated individuals. [Table 4](#dyv370-T4){ref-type="table"} summarizes the data and biological samples collected during baseline, active follow-up and post-season phases. We additionally linked participants' data to small area statistics such as the index of multiple deprivation and rural/urban indicators.[@dyv370-B16]^,^[@dyv370-B17] Details of the T cell methodology have been described previously.[@dyv370-B18]Table 4.Questionnaire data and biological samples collected in three data collection periodsPhaseData typeMeasurementSeason123456**Baseline/Pre-seasonSelf-reported surveys**Basic demographic, socioeconomic, health, vaccination and potential risk factors for influenzaXXXXXXQuality of life (EQ5D)X**Blood samples**H1N1, H3N2 and Flu B serology[^a^](#tblfn4){ref-type="table-fn"}XXXH1N1pdm09 serological[^a^](#tblfn4){ref-type="table-fn"}XXXT cell analysis[^b^](#tblfn5){ref-type="table-fn"}XXXX**Active follow-upSelf-reported surveys**Timing and characteristics of respiratory illnesses (if ill)XXXXXXRisk factors in previous week (if ill)XXXTime off work/education (if ill)XXXXHealth-seeking behaviour and medicines taken (if ill)XXFull contact and activity diaries (if ill)XXBasic contact and activities (if ill)XInfluenza vaccination that weekXXXFull contact and activity diaries (one-off survey)XXXXXXIndoor/outdoor temperature and humidity (one-off surveys)XXXDetailed travel survey (one-off survey)X**Self-administered nasal swabs**RT-PCR Influenza A (H1 and H3 subtypes), influenza B, RSV and human metapneumovirusXXXXXXRT-PCR influenza A H1N1pdm09XXXRT-PCR rhinovirus, coronavirus, adenovirus and para-influenza virus[^c^](#tblfn6){ref-type="table-fn"}XXXXXXSelected viral samples genetically sequencedXXXXXX**Blood samples**[**^d^**](#tblfn7){ref-type="table-fn"}H1N1pdm09 serologyX**Post-seasonSelf-reported surveys**Changed household composition, pregnancy, vaccination, hospitalization, death and air travelXXXXXXIllness-reporting behaviour during follow-upXXXAttitudes towards vaccination and antiviralsXX**Medical records**[**^e^**](#tblfn8){ref-type="table-fn"}Chronic illness, vaccination, prescriptions, GP and hospital consultations and deathXXXXXX**Blood samples**H1N1, H3N2 and flu B serology[^a^](#tblfn4){ref-type="table-fn"}XXXH1N1pdm09 serology[^a^](#tblfn4){ref-type="table-fn"}XXT cell analysis[^b^](#tblfn5){ref-type="table-fn"}XX**Saliva Samples**[**^f^**](#tblfn9){ref-type="table-fn"}Genetic analysisXXXXXX[^4][^5][^6][^7][^8][^9]

What has been found? Key findings and publications
==================================================

Our first publication provided comprehensive national estimates of clinical and sub-clinical disease burden in the community regardless of consultations, and allowed comparison between seasonal and pandemic influenza.[@dyv370-B2] We found that on average, influenza infected 18% of unvaccinated people each winter and up to 75% of these infections were asymptomatic. Approximately 25% of infections were PCR confirmed and only 17% of people with PCR-confirmed disease sought medical attention; [Figure 2](#dyv370-F2){ref-type="fig"} indicates how the primary care-based surveillance underestimated the burden of infection in the community. Results were similar between pandemic and seasonal influenza, although people infected with the 2009 pandemic strain had less severe symptoms than those infected with seasonal H3N2 strains.

![Number of expected events in a surveillance practice serving a population of 10 000: data for a typical influenza season.](dyv370f2){#dyv370-F2}

Our second publication provided strong evidence that naturally occurring, cross-protective T cell immunity protects those infected with influenza against developing disease in seasonal and pandemic periods.[@dyv370-B16] This protection was independent of baseline antibodies and protective levels of influenza-specific T cells were found in 43% of the population. These findings help explain why such a large proportion of infections remain asymptomatic and have implications for the development of cross-protective 'universal' vaccines based on this response.

In order to evaluate different methods of collecting data during a pandemic, we compared prospectively collected Flu Watch data on illnesses and vaccine uptake with retrospectively collected data from the Health Survey for England.[@dyv370-B21] We found that retrospectively collected data underestimated disease burden but accurately estimated vaccine uptake when compared with prospectively collected data.

Current work includes an analysis of occupational exposure to pigs as a risk factor for human infection with swine and human influenza viruses; age as a predictor of T cell responses; and a comparison of serological pandemic infection rates from Flu Watch and the Health Survey for England.

What are the main strengths and weaknesses?
===========================================

Flu watch is a large community cohort study broadly representative of the population of England. It is the first modern-day household study of influenza transmission in a temperate climate, comparable to the landmark Tecumseh studies of the 1960s and 70s.[@dyv370-B22] A major strength is the inclusion of different household types (rather than just households with children, as in earlier studies) which allows influenza infections to be explored across the whole of society. We used highly active methods of surveillance for influenza and other respiratory viruses, exploiting a range of IT-based technologies including automated telephone surveys, e-mail, internet and text messages. Broadly similar methods of follow-up were used across six influenza seasons, allowing accurate comparisons of disease burden estimates between seasonal and pandemic influenza despite external factors (such as media reporting during the pandemic) that may have affected consultation behaviour. Robust definitions of influenza were based on a range of diagnostic methods including real-time symptom reporting, PCR and serology, allowing the emergence of the 2009 H1N1 pandemic strain to be tracked. Serological and virological data from previous pandemics are either unavailable (1918 H1N1 pandemic), from small samples sizes (1957 H2N2 pandemic)[@dyv370-B23] or from populations with high vaccination rates which greatly limits interpretation (1968 H3N2 pandemic).[@dyv370-B22] Historical data on laboratory-confirmed rates of seasonal influenza mainly come from historical community studies of families in the USA between 1948 and 1981.[@dyv370-B10]^,^[@dyv370-B22]^,^[@dyv370-B24]^,^[@dyv370-B25] Flu Watch is a good example of collaboration between disciplines (epidemiology, immunology, virology and primary care) and partners. The study provides a rich source of data on social, behavioural and biological factors affecting influenza transmission, enabling exploration of many research questions.

Limitations include delays in obtaining funding, ethics and R&D approval across multiple sites, resulting in delayed recruitment during the pandemic and fewer participants overall. Although the initial response to invitation letters was low, it is unclear if this would bias results. Ideally, cohorts would have had pre- and post-influenza season bleeds, but recruitment periods were not perfectly streamlined with influenza seasons so adjustments for bleed timings were made during analysis. The study design and data collection methods evolved in response to experience and changing questions. Whereas this optimized and streamlined methods, it also increased complexity of data management.

Can I get hold of the data? Where can I find out more
=====================================================

For further information about Flu Watch see \[<http://www.fluwatch.co.uk/>\]. Currently data are not open access but strategic collaborations are welcomed. Please address enquiries to Professor Andrew Hayward \[a.hayward\@ucl.ac.uk\].

Flu watch profile in a NutshellFlu Watch is a national prospective cohort study of influenza in English households.It aimed to measure clinical and sub-clinical infection in the community, investigate socio-demographic and behavioural risk factors for influenza and generate novel data on antibody and T cell immunity, to inform influenza control initiatives.A total of 5484 participants were recruited from 2205 households randomly selected from registers of participating general practices.Participants were followed up for 118 158 person-weeks through six periods of influenza circulation: the winter seasons 2006/07, 2007/08 and2008/09, the summer 2009 pandemic wave, the winter 2009/10 pandemic wave and the post pandemic season 2010/11.The dataset comprises a wide range of demographic, social and behavioural measures, active weekly surveillance for respiratory illnesses and biological samples (nasal swabs, serology and T cells).Data are not currently open access but strategic collaborations are welcomed: enquiries to \[a.hayward\@ucl.ac.uk\].
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[^1]: \*Vaccinated for that influenza season (before or during follow-up).

[^2]: ^a^We believe the poor response in this season may be due to summer holidays.

[^3]: \*Vaccinated for that influenza season (before or during follow-up).

[^4]: ^a^Haemagglutination-inhibition assay.

[^5]: ^b^Peripheral blood mononuclear cells (PBMC) separated, part of the sample was immediately tested against pools of peptides representing each of the virus proteins in an ex vivo IFN-γelispot assay.[@dyv370-B18]^,^[@dyv370-B19] The rest of the sample was frozen down for more detailed peptide mapping studies using IFN-γelispots and/or in vitro culture and testing by intracellular cytokine staining to determine CD8/4 restriction. Post-season T cell analysis was only conducted in seasons 1 and 3.

[^6]: ^c^Only a selection of nasal swab samples were tested for these viruses in seasons 5 and 6.

[^7]: ^d^Only taken from participants in T cell and serology cohorts before influenza vaccination.

[^8]: ^e^Medical record checks were requested for all participants except those in the virology cohort.

[^9]: ^f^Saliva was collected in 2011--12 from selected participants participating from all seasons and cohorts.
